


Anti-Vi IgG and IgA Persistence following Immunisation with Vi Conjugate and Polysaccharide Vaccines

Lizzy Jones


27th March 2019

Vaccines Against *Salmonella Typhi* Oxford typhoid fever Controlled Human Infection Model (CHIM)




Typhoid Diagnosis defined as fever $\geq 38^{\circ}\text{C}$ for >12 hours or positive blood culture

Vi-vaccination reduces Typhoid Fever cases by >50%







Jin et al., *Lancet* (2017)

Higher anti-Vi IgG, IgG2 and IgA titres are associated with a decreased risk of typhoid fever diagnosis





Slide courtesy of Celina Jin


High anti-Vi IgG and IgA titres persist 13 months post Vi-vaccination (no significant difference between Vi-TT and Vi-PS)



High anti-Vi IgG and IgA titres persist 13 months post Vi-vaccination



Persistence of antibody effector functions in response to Vi vaccination




Infographic courtesy of Bonnie Gunn, Ragon Institute.


 **Ragon Institute**
of MGH, MIT and Harvard

Long lasting functional antibodies produced in response to Vi vaccination


Antibody dependent Cellular Phagocytosis




Antibody Dependent Neutrophil Phagocytosis



Antibody Dependent Complement Deposition



Antibody Dependent NK cell Degranulation



Graphs courtesy of Celina Jin and Jenny Hill



www.ovg.ox.ac.uk

Acknowledgements



Volunteers

OVG Typhoid Study Team

BILL & MELINDA
GATES foundation

Binding Site
THE BINDING SITE

Ragon Institute
of MGH, MIT and Harvard




Bharat Biotech

BILL & MELINDA
GATES foundation

AADITEC
Advanced Immunisation Technologies


NHS
National Institute for
Health Research

Vaccination with Vi-TT induces higher levels of functional antibody




Exposure to S. Typhi 1 month after does result in a boost in Vi antibody titres


Comparison of antibody persistence in vaccinated and exposed individuals




Anti-Vi IgG responses to Vi-TCV in a controlled human infection model



Anti-Vi IgG responses to Vi-TCV in a controlled human infection model




One month post-vaccination, Fc-mediated functional responses are significantly higher in Vi-TT than Vi-PS vaccinees






Antibody-dependent
Complement deposition



Antibody-dependent
Cellular (macrophage) phagocytosis



Antibody-dependent
Neutrophil phagocytosis




 Ragon Institute
of MGH, MIT and Harvard

BILL & MELINDA
GATES foundation


ADITEC
Advanced Immunotherapy Technologies


National Institute for
Health Research

Vi-TT vaccination increases NK cell degranulation one month post-vaccination in comparison with Vi-PS



 Ragon Institute
of MGH, MIT and Harvard